![IASLC Webinars](/sites/default/files/styles/d08_standard/public/2021-09/MicrosoftTeams-image%20%285%29.png?h=136bfe02&itok=WRleAWOS)
Join Drs. Harpole, Higgins, and Stinchcombe as they discuss the latest developments presented during the scientific and educational program at 2021 World Conference on Lung Cancer Worldwide Virtual Event. The webinar will consist of three 15 minute presentations followed by a 15 minute time for question and answers.
Friday, October 1, 2021
2 PM MDT
4 PM EDT
At the conclusion of this activity, participants will be able to:
- Describe scientific progress in the prevention, early detection, diagnosis and treatment of thoracic malignancies.
- Explain advances in the multidisciplinary management of patients in relation to current standards of care.
- Identify the most relevant clinical research results and ongoing trials likely to impact patient care in the near future.
This webinar is designed to meet the educational needs of physicians, nurses and allied health professionals, pharmacists, patient advocates, and researchers who specialize in diagnostic radiology, hematology, pulmonary medicine, palliative care, medical oncology, thoracic surgery, and radiation oncology.
Accreditation Statement
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The International Association for the Study of Lung Cancer designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Dr. Kristin Higgins
- Nothing to Disclose
Dr. David Harpole
- Scientific Advisory Board: AstraZeneca, Medtronic, Novartis
- Steering Committee: AEGEAN
Dr. Thomas Stinchcombe
- Advisory Board (ended): Takeda, AstraZeneca, Genentech/Roche, Foundation Medicine, Pfizer, EMD Serono, Novartis, Daiichi Sankyo, Lilly, Medtronic, Puma Biotechnology, Janssen Oncology, Regeneron
- Research funding from ineligible companies: Genentech/Roche, Blueprint Medicines, AstraZeneca, Takeda, Advaxis, Regeneron (institution)
Friday, October 1, 2021
2 PM MDT
4 PM EDT
At the conclusion of this activity, participants will be able to:
- Describe scientific progress in the prevention, early detection, diagnosis and treatment of thoracic malignancies.
- Explain advances in the multidisciplinary management of patients in relation to current standards of care.
- Identify the most relevant clinical research results and ongoing trials likely to impact patient care in the near future.
This webinar is designed to meet the educational needs of physicians, nurses and allied health professionals, pharmacists, patient advocates, and researchers who specialize in diagnostic radiology, hematology, pulmonary medicine, palliative care, medical oncology, thoracic surgery, and radiation oncology.
Accreditation Statement
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
The International Association for the Study of Lung Cancer designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Dr. Kristin Higgins
- Nothing to Disclose
Dr. David Harpole
- Scientific Advisory Board: AstraZeneca, Medtronic, Novartis
- Steering Committee: AEGEAN
Dr. Thomas Stinchcombe
- Advisory Board (ended): Takeda, AstraZeneca, Genentech/Roche, Foundation Medicine, Pfizer, EMD Serono, Novartis, Daiichi Sankyo, Lilly, Medtronic, Puma Biotechnology, Janssen Oncology, Regeneron
- Research funding from ineligible companies: Genentech/Roche, Blueprint Medicines, AstraZeneca, Takeda, Advaxis, Regeneron (institution)